Future oncology (London, England) · 2021
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hájek Roman, Minařík Jiří, Straub Jan, Pour Luděk, Jungova Alexandra, Berdeja Jesus G, Boccadoro Mario, Brozova Lucie, Spencer Andrew, van Rhee Frits, Vela-Ojeda Jorge, Thompson Michael A, Abonour Rafat, Chari Ajai, Cook Gordon, Costello Caitlin L, Davies Faith E, Hungria Vania Tm, Lee Hans C, Leleu Xavier, Puig Noemi, Rifkin Robert M, Terpos Evangelos, Usmani Saad Z, Weisel Katja C, Zonder Jeffrey A, Bařinová Magda, Kuhn Matyáš, Šilar Jiří, Čápková Lenka, Galvez Kenny, Lu Jin, Elliott Jennifer, Stull Dawn Marie, Ren Kaili, Maisnar Vladimír
Аннотация
Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov).